Mary Wilson
Well-known member
BY SELINA KOCH, EXECUTIVE EDITOR
NOV 18, 2020 | 8:05 PM CST
Strong efficacy data from the two leading COVID-19 vaccines suggest the window for testing additional vaccine candidates in the U.S. could soon start to close.
Of the more than 200 vaccines in development for COVID-19, at least seven have a chance of gathering pivotal data before the first front-runners become broadly available, making recruitment difficult.
... “By the time the vaccine starts to be laid out you may, as an individual, only have access to the vaccine in a month and a half or two months. If you participate in a clinical trial, you have a 50% chance you have access to the vaccine tomorrow.”
With protection rates of 95% and two-month safety data in or imminent, Moncef Slaoui, chief scientific adviser to Operation Warp Speed, said in a briefing Wednesday that he expects emergency use authorizations (EUAs) for BNT162b2 from Pfizer Inc. (NYSE
FE) and BioNTech SE (NASDAQ:BNTX) and mRNA-1273 from Moderna Inc. (NASDAQ:MRNA) to come as early as the middle of December.
EUAs for the first candidates could hinder trial recruitment in at least two ways.
https://www.biocentury.com/article/632064
NOV 18, 2020 | 8:05 PM CST
Strong efficacy data from the two leading COVID-19 vaccines suggest the window for testing additional vaccine candidates in the U.S. could soon start to close.
Of the more than 200 vaccines in development for COVID-19, at least seven have a chance of gathering pivotal data before the first front-runners become broadly available, making recruitment difficult.
... “By the time the vaccine starts to be laid out you may, as an individual, only have access to the vaccine in a month and a half or two months. If you participate in a clinical trial, you have a 50% chance you have access to the vaccine tomorrow.”
With protection rates of 95% and two-month safety data in or imminent, Moncef Slaoui, chief scientific adviser to Operation Warp Speed, said in a briefing Wednesday that he expects emergency use authorizations (EUAs) for BNT162b2 from Pfizer Inc. (NYSE
FE) and BioNTech SE (NASDAQ:BNTX) and mRNA-1273 from Moderna Inc. (NASDAQ:MRNA) to come as early as the middle of December.EUAs for the first candidates could hinder trial recruitment in at least two ways.
https://www.biocentury.com/article/632064